用于哮喘的抗炎缓解疗法（AIR）
Anti-inflammatory reliever therapy (AIR) for asthma.
作者信息
Levy Mark L, Crooks Michael G
机构信息
Kenton Bridge Medical Centre, Harrow, UK.
Hull York Medical School, University of Hull, Hull, UK.
出版信息
ERJ Open Res. 2024 Sep 30;10(5). doi: 10.1183/23120541.00494-2024. eCollection 2024 Sep.
Abstract
摘要
https://bit.ly/4aHOLn8. （此为网址，无法准确翻译为中文，保留原文即可）
相似文献
1
Anti-inflammatory reliever therapy (AIR) for asthma.用于哮喘的抗炎缓解疗法（AIR）
ERJ Open Res. 2024 Sep 30;10(5). doi: 10.1183/23120541.00494-2024. eCollection 2024 Sep.
2
The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today.ICS 药物在今日哮喘管理中的救治疗法地位：ICS 与单用 SABA 之比较。
J Allergy Clin Immunol Pract. 2024 Apr;12(4):870-879. doi: 10.1016/j.jaip.2024.01.011. Epub 2024 Jan 17.
3
Effective Asthma Management: Is It Time to Let the AIR out of SABA?有效的哮喘管理：是时候减少短效β2激动剂的使用了吗？
J Clin Med. 2020 Mar 27;9(4):921. doi: 10.3390/jcm9040921.
4
[Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma].[布地奈德/福莫特罗维持与缓解治疗。一种针对成年哮喘患者的新治疗方法]
Med Klin (Munich). 2008 May 15;103(5):299-310. doi: 10.1007/s00063-008-1050-y.
5
It is time to change the way we manage mild asthma: an update in GINA 2019.是时候改变我们治疗轻度哮喘的方式了：GINA 2019 更新。
Respir Res. 2019 Aug 14;20(1):183. doi: 10.1186/s12931-019-1159-y.
6
Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma.布地奈德/福莫特罗维持和缓解治疗：成人哮喘患者的一种新治疗方法。
Curr Med Res Opin. 2007 Aug;23(8):1867-78. doi: 10.1185/030079907X210769.
7
The management of mild asthma.轻度哮喘的管理。
Eur Respir J. 2021 Apr 8;57(4). doi: 10.1183/13993003.03051-2020. Print 2021 Apr.
8
What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?从布地奈德/福莫特罗作为维持和缓解药物的试验中，我们了解到了哪些关于哮喘控制的知识？
Respirology. 2020 Aug;25(8):804-815. doi: 10.1111/resp.13804. Epub 2020 Mar 31.
9
The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription.哮喘管理领域的变化与适当 SABA 处方的需求。
Adv Ther. 2023 Apr;40(4):1301-1316. doi: 10.1007/s12325-022-02410-z. Epub 2023 Jan 30.
10
SABAs as Reliever Medications in Asthma Management: Evidence-Based Science.SABA 作为哮喘管理中的缓解药物：基于证据的科学。
Adv Ther. 2023 Jul;40(7):2927-2943. doi: 10.1007/s12325-023-02543-9. Epub 2023 Jun 7.
本文引用的文献
1
Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials.用于重度哮喘的生物制剂：随机对照试验的系统评价和荟萃分析
Eur Respir Rev. 2024 Apr 24;33(172). doi: 10.1183/16000617.0238-2023. Print 2024 Apr 30.
2
Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia.短效β2受体激动剂处方及相关临床结局评估：亚洲哮喘患者使用短效β2受体激动剂（SABINA）研究的结果
World Allergy Organ J. 2023 Oct 16;16(10):100823. doi: 10.1016/j.waojou.2023.100823. eCollection 2023 Oct.
3
Questions in Mild Asthma: An Official American Thoracic Society Research Statement.轻度哮喘问题：美国胸科学会官方研究声明
Am J Respir Crit Care Med. 2023 Jun 1;207(11):e77-e96. doi: 10.1164/rccm.202304-0642ST.
4
Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site.通过实施SENTINEL计划改善哮喘护理：试点站点的研究结果。
ERJ Open Res. 2023 May 9;9(3). doi: 10.1183/23120541.00685-2022. eCollection 2023 May.
5
The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review.ICS/福莫特罗缓解治疗方案在哮喘中的应用：综述。
J Allergy Clin Immunol Pract. 2023 Mar;11(3):762-772.e1. doi: 10.1016/j.jaip.2023.01.002. Epub 2023 Jan 10.
6
SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada).使用短效β2激动剂作为哮喘急性加重风险的指标：一项观察性队列研究（加拿大SABINA研究）
ERJ Open Res. 2022 Sep 26;8(3). doi: 10.1183/23120541.00140-2022. eCollection 2022 Jul.
7
Over-prescription of short-acting β-agonists is associated with poor asthma outcomes: results from the Latin American cohort of the SABINA III study.短效β受体激动剂的过度处方与哮喘不良结局相关：SABINA III研究拉丁美洲队列的结果
J Asthma. 2023 Mar;60(3):574-587. doi: 10.1080/02770903.2022.2082305. Epub 2022 Jun 20.
8
Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide.基于血液嗜酸性粒细胞和呼出气一氧化氮的哮喘发作风险原型量表的推导。
Thorax. 2022 Feb;77(2):199-202. doi: 10.1136/thoraxjnl-2021-217325. Epub 2021 Aug 6.
9
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.按需使用固定剂量β激动剂和类固醇吸入剂治疗轻度哮喘的成人或儿童。
Cochrane Database Syst Rev. 2021 May 4;5(5):CD013518. doi: 10.1002/14651858.CD013518.pub2.
10
Identifying the drivers of patients' reliance on short-acting β2-agonists in asthma.确定哮喘患者对短效β2-激动剂依赖的驱动因素。
J Asthma. 2021 Aug;58(8):1094-1101. doi: 10.1080/02770903.2020.1761382. Epub 2020 May 29.
Zotero 插件